<DOC>
	<DOCNO>NCT02903914</DOCNO>
	<brief_summary>This study open-label Phase 1 evaluation CB-1158 single agent combination immune checkpoint therapy patient advanced/metastatic solid tumor .</brief_summary>
	<brief_title>Arginase Inhibitor CB-1158 Patients With Solid Tumors</brief_title>
	<detailed_description>This study open-label Phase 1 evaluation CB-1158 single agent combination immune checkpoint therapy patient advanced/metastatic solid tumor . Single Agent CB-1158 : Patients advanced/metastatic solid tumor enrol escalate monotherapy dose cohort determine Recommended Phase 2 Dose ( RP2D ) CB-1158 . Additional patient NSCLC , CRC , tumor enrol single agent RP2D . Combination Treatment : Patients advanced/metastatic clear cell renal cell carcinoma , melanoma , non-small cell lung cancer solid tumor previously treat PD-1 PD-L1 therapy enrol separate cohort combination therapy ( CB-1158 nivolumab ) determine RP2D . Additional patient NSCLC melanoma enrol combination CB-1158 nivolumab RP2D . All patient assess safety , pharmacokinetics , biomarkers tumor response .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>*Additional cohort specific criterion may apply Ability provide write informed consent accordance federal , local , institutional guideline Histological cytological diagnosis metastatic cancer locally advance cancer amenable local therapy Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Life Expectancy least 3 month Adequate hepatic , renal , cardiac , hematologic function Measurable disease RECISTv1.1 criterion Resolution treatmentrelated toxicity Unable receive oral medication Unable receive oral IV hydration Intolerance prior antiPD1/PDL1 therapy Prior severe hypersensitivity reaction another monoclonal antibody ( mAb ) Any current previous malignancy within 3 year except protocol allow malignancy Chemotherapy , Tyrosine Kinase Inhibitor therapy , radiation therapy hormonal therapy within 2 week Immunotherapy biological therapy , investigational agent within 3 week ( Note : cohort exception allow antiPD1 therapy ) Active know suspect exclusionary autoimmune disease Any condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) systemic immunosuppressive medication within 2 week History known risk factor bowel perforation Symptomatic ascites pleural effusion Major surgery within 28 day Cycle 1 Day 1 Active infection require within 2 week prior first dose study drug Patients HIV , Hepatitis B C Conditions could interfere treatment protocolrelated procedure Active , nonstable brain metastasis CNS disease Known deficiency suspect defect urea cycle</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Immuno-Oncology</keyword>
	<keyword>Checkpoint Inhibitors</keyword>
	<keyword>Tumor Metabolism</keyword>
	<keyword>PD-1 inhibitor</keyword>
	<keyword>PD-L1 inhibitor</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>RCC</keyword>
	<keyword>MEL</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Arginase</keyword>
	<keyword>Arginase Inhibitor</keyword>
	<keyword>CB-1158</keyword>
	<keyword>SCCHN</keyword>
	<keyword>GEJ</keyword>
</DOC>